Ribbon Cutting – Foundation Medicine

On Tuesday, August 9, Foundation Medicine hosted a grand opening and ribbon cutting ceremony at its new state-of-the-art lab facility in San Diego.  With nearly 100 guests in attendance, the celebratory event kicked off with breakfast and opening remarks from CEO Brian Alexander, Chief Scientific Officer Priti Hegde and San Diego Site Lead Steven Springer. They each spoke to the significance of having a presence in the heart of San Diego’s life science cluster and how this facility will serve as another strong hub for early research and increase capacity for the company’s FoundationOne® Liquid CDx liquid biopsy test — all of which will accelerate the goal of advancing personalized medicine for patients. Following the opening remarks, a ribbon cutting took place as guests cheered on. Guests were invited to stay for a lunch recaption and take a tour of the clinical lab.

Foundation Medicine is a pioneer in molecular profiling for cancer, working to shape the future of clinical care and research. We collaborate with a broad range of partners across the cancer community and strive to set the standard for quality, scientific excellence, and regulatory leadership. Our deep understanding of cancer biology helps physicians make informed treatment decisions for their patients and empowers researchers to develop new medicines. Every day, we are driven to help our partners find answers and take action, enabling more people around the world to benefit from precision cancer care. For more information, please visit us on and follow us on Twitter and LinkedIn.

About FoundationOne® Liquid CDx
FoundationOne Liquid CDx is a qualitative next generation sequencing based in vitro diagnostic test for prescription use only that uses targeted high throughput hybridization-based capture technology to analyze 324 genes utilizing circulating cell-free DNA (cfDNA) isolated from plasma derived from anti-coagulated peripheral whole blood of advanced cancer patients. The test is FDA-approved to report short variants in over 300 genes and is a companion diagnostic to identify patients who may benefit from treatment with specific therapies (listed in Table 1 of the Intended Use) in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Patients who are negative for companion diagnostic mutations should be reflexed to tumor tissue testing and mutation status confirmed using an FDA-approved tumor tissue test, if feasible. For the complete label, including companion diagnostic indications and complete risk information, please visit